Dr.Β Joong BaeΒ Ahn
MD, MSc, PhD
Professor, Medical Oncology β Gastrointestinal Oncology
corporate_fareYonsei Cancer Center, Seoul, South Korea
Joong Bae Ahn
MD, MSc, PhD
Prof. Joong Bae Ahn is a Professor in the Department of Internal Medicine and a specialist in the Division of Medical Oncology at Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. He has dedicated more than three decades to clinical and research work in gastrointestinal oncology, with a particular focus on colorectal cancer.
Prof. Ahn obtained his MD from Yonsei University in 1990, followed by an MSc in 1994 and a PhD from Yonsei University College of Medicine in 2003. His career has spanned residency and fellowship training at Yonsei Medical Center, an appointment at National Health Insurance Ilsan Hospital, and a professorship at Yonsei University College of Medicine from 2005 onwards. He has authored or co-authored 177 articles listed in the Yonsei University Medical Library's YUHSpace researcher profile and has contributed as a principal investigator in clinical trials registered on ClinicalTrials.gov, including studies in metastatic colorectal cancer and hepatic arterial infusion therapy. His research spans chemotherapy, targeted agents, immune checkpoint inhibitors, biomarker testing, and precision oncology in advanced colorectal cancer.
CancerFax can coordinate medical-report review, case preparation, and consultation support for international patients seeking an opinion from Prof. Joong Bae Ahn at Yonsei Cancer Center.
Why Consider Prof. Joong Bae Ahn?
Prof. Joong Bae Ahn brings more than 30 years of dedicated medical oncology practice to the treatment of colorectal cancer, supported by an extensive academic and clinical research record at one of South Korea's leading cancer centres.
Areas of Specialisation
Prof. Ahn's clinical practice focuses on systemic treatment for colorectal and gastrointestinal cancers, including advanced, metastatic, and biomarker-defined disease settings.
Prof. Joong Bae Ahn's specialisation is medical oncology for gastrointestinal cancers, with particular depth in colorectal cancer at all stages. His approach incorporates chemotherapy, targeted therapy, immunotherapy, and biomarker-guided treatment planning within a multidisciplinary cancer care framework.
Colorectal Cancer β Systemic Therapy
Chemotherapy and biologic combinations for colon, rectal, and metastatic colorectal cancer.
- arrow_rightFOLFIRI (5-fluorouracil, leucovorin, irinotecan) for recurrent or metastatic colorectal cancer
- arrow_rightChemotherapy duration planning for stage II and III colon cancer
- arrow_rightOxaliplatin and fluoropyrimidine-based adjuvant therapy
- arrow_rightCetuximab-based therapy for KRAS wild-type metastatic colorectal cancer
- arrow_rightBevacizumab-based therapy for metastatic colorectal cancer
- arrow_rightRegorafenib for advanced or refractory colorectal cancer
- arrow_rightMolecularly guided treatment selection based on KRAS and biomarker profiling
Immunotherapy & Precision Oncology
Immune checkpoint inhibitors and genomic profiling in eligible colorectal cancer patients.
- arrow_rightAvelumab and durvalumab studies in MSI-H or dMMR metastatic/unresectable colorectal cancer
- arrow_rightImmunotherapy for POLE-mutated advanced colorectal cancer
- arrow_rightBiomarker assessment to identify immunotherapy-eligible patients
- arrow_rightKRAS mutation testing and molecular profiling in colorectal cancer
- arrow_rightCirculating tumour biomarker research
- arrow_rightPrecision oncology approaches in advanced gastrointestinal malignancies
Procedures & Treatment Approaches
Medical oncology services for colorectal and gastrointestinal cancers
Prof. Ahn provides systemic cancer treatment through medical oncology, including chemotherapy, targeted therapy, immunotherapy, and clinical trialβbased care. Treatment is delivered within Yonsei Cancer Center's multidisciplinary framework, coordinating with surgical, gastroenterological, and radiation oncology teams where required.
Systemic Chemotherapy
Medical OncologyChemotherapy planning and administration for colorectal cancer at all stages.
Targeted & Biologic Therapy
Targeted TherapyMolecularly targeted treatment planning for eligible colorectal cancer patients.
Immunotherapy
Medical OncologyImmune checkpoint inhibitor therapy for biomarker-selected colorectal cancer patients.
Second Opinion & Case Review
Second OpinionSpecialist case review for complex or metastatic colorectal cancer.
Research & Publications
Peer-reviewed contributions in colorectal cancer and gastrointestinal oncology
Prof. Joong Bae Ahn has an extensive academic record. The Yonsei University Medical Library YUHSpace researcher profile lists 177 articles under his name, covering metastatic colorectal cancer, targeted therapy, immunotherapy, biomarker research, and clinical trial design in gastrointestinal oncology.
Prof. Ahn's complete publication list is available via ORCID (0000-0001-6787-1503) and the Yonsei University Medical Library YUHSpace researcher profile.
Education & Training
Prof. Joong Bae Ahn completed all three of his academic degrees at Yonsei University, Seoul, progressing from undergraduate medical training through to doctoral research in oncology.
Clinical Experience
Prof. Ahn has worked in academic medical oncology at Yonsei University College of Medicine since 2005 and has been affiliated with Yonsei Cancer Center throughout this period. His career includes prior appointments at National Health Insurance Ilsan Hospital and fellowship training at Yonsei University.
Languages & International
Prof. Joong Bae Ahn consults in Korean. Yonsei Cancer Center's International Health Care Center provides translation and interpreting services for foreign patients in English, Japanese, Russian, and Chinese, with other languages arranged on request.
Severance Hospital's International Health Care Center reports more than 50,000 foreign patient visits annually and provides structured support including interpreter services, appointment coordination, and billing assistance for international patients.
Yonsei Cancer Center supports international patients through its International Health Care Center, offering interpreting in English, Japanese, Russian, and Chinese. CancerFax can also coordinate additional medical interpreter support where required.
How CancerFax Helps You Access Dr. Joong Bae Ahn
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Joong Bae Ahn's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Joong Bae Ahn's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Joong Bae Ahn before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Joong Bae Ahn's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Joong Bae Ahn's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Joong Bae Ahn's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Joong Bae Ahn
Prof. Ahn specialises in medical oncology for colorectal cancer, including colon cancer, rectal cancer, metastatic colorectal cancer, and colorectal cancer with liver or lung metastases. His research and clinical work also cover MSI-H and mismatch repair-deficient colorectal cancer, POLE-mutated colorectal cancer, and gastrointestinal stromal tumour (GIST).
Prof. Ahn is affiliated with Yonsei Cancer Center and Yonsei University College of Medicine in Seoul, South Korea. He holds a professorship in the Department of Internal Medicine and works within the Division of Medical Oncology at Yonsei Cancer Center.
Yonsei Cancer Center's International Health Care Center supports foreign patients and provides interpreting services in English, Japanese, Russian, and Chinese. CancerFax can coordinate medical-report review and consultation support for international patients, subject to hospital availability and case acceptance.
Submit your medical reports through CancerFax. The CancerFax team will review your documents, prepare the case summary, and coordinate the next steps with Yonsei Cancer Center, subject to the doctor's availability and institutional case-acceptance process.
Prof. Ahn's verified treatment expertise includes FOLFIRI-based chemotherapy, adjuvant oxaliplatin and fluoropyrimidine regimens, cetuximab and bevacizumab for metastatic colorectal cancer, regorafenib for advanced disease, and immune checkpoint inhibitor therapy (avelumab, durvalumab) in MSI-H or dMMR and POLE-mutated colorectal cancer. His work also includes biomarker-guided and molecular profiling-based treatment planning.
Yes. Prof. Ahn is listed on ClinicalTrials.gov as a principal investigator in studies including a phase II trial comparing hepatic arterial infusion combined with systemic chemotherapy for colorectal liver metastases (NCT05103020) and a bevacizumab and cetuximab pattern-of-use study in metastatic colorectal cancer (NCT03286738). Eligibility for any trial depends on the patient's specific clinical profile and the trial's current enrolment status.
Connect with Joong Bae Ahn Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.